Neurocrine Biosciences | NBIX - صافي الدخل





صافي الدخل تغيير تاريخ
AbbVie USD 1.82B 1.63B 2025-12
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
ALKERMES USD 49.34M 33.42M 2025-12
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
Amgen USD 1.33B 1.88B 2025-12
Biogen USD 466.5M 168.3M 2025-09
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Cytokinetics USD -183.03M 123.15M 2025-12
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Exelixis USD 193.58M 8.73M 2025-09
Gilead Sciences USD 2.18B 869M 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Incyte USD 299.28M 124.89M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
Nektar Therapeutics USD -37.06M 15.31M 2024-09
Neurocrine Biosciences USD 209.5M 102M 2025-09
Pfizer USD -1.65B 5.19B 2025-12
Prothena USD -21.59M 14.95M 2025-12
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Repligen USD 13.29M 1.62M 2025-12
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Teva Pharmaceutical Industries USD 480M 47M 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Vertex Pharmaceuticals USD 1.19B 108.2M 2025-12
Xoma USD -17.24M 33.23M 2024-09